Page 63 - MemoriaCIBER-2018ENG

On the organisational level we should not fail to mention the application by the Management of the CIBEREHD of a strategic approach to redirect the scientific work of the groups more
Gastrointestinal physiopathology: inflammatory bowel disease and motility disorders
Coordinator:
Pere Clavé Civit
Clinical-scientific relevance of the
subjects in the programme
This programme includes digestive
diseases of great prevalence and impact
on the public’s health and quality of the
life, structured in three overall lines: a) Oesophageal–gastroduodenal pathology;
b) Inflammatory bowel syndrome; and
c) Neuro-gastroenterology, alterations of digestive motility and functional disorders. Knowledge of the physiopathology, diagnosis, epidemiology, prevention and treatment
of these diseases is furthered by means of cooperative and multidisciplinary research done by researchers in clinical, basic and epidemiological approaches. At the same time, a line of cooperation was created between basic researchers in the area by means of a strategic IntraCIBEREHD action which involves most
of the groups. During 2018 the merger of two research groups was consolidated, one group joined, Group Leaders were renewed and one European H2020 (Cost-Action) measure was taken on with the leadership of the CIBEREHD and co-financed by the European Society for Swallowing Disorders.
a) Oesophageal-gastro-duodenal pathology.
The innovations in 2018 in this area focus on the development of pharmacological strategies, the publication of different guidelines and consensuses on the strategies for eradicating infection by helicobacter pylorii in cases
of resistance to first-line treatments. We
traditionally engaged in research into hepatitis C, taking into account the great effectiveness of antiviral therapy which has fortunately enabled most of the patients to be cured.
should also highlight the publications led by CIBEREHD researchers of the studies from
the European Registry on the management
of Helicobacter pylori infection (Hp-EuReg) enabling starting the implementation of a map of response to treatment and resistances with a European perspective. The study of the adverse effects of non-steroidal anti-inflammatory drugs on peptic disease and its complications continues to take a relevant place in this
line of research, as well as new studies on oesophageal-gastric cancer.
b) Inflammatory Bowel Disease.
This continues to be the most productive line in this area and the one to which most human and material resources are allocated. Research is aimed at the primary causes of immune dysfunction and recognition of genetic and environmental determinants conditioning
the phenotypic development of each IBD, the development and assessment of new diagnostic methods and for monitoring the disease,
as well as developing new treatments. The results for 2018 are very relevant as regards
the treatment of perianal Crohn’s disease with stem cells, the publication of many studies
and clinical trials comparing the effectiveness and safety of different immune-modulation treatments in different phases of the disease (active/remission) and the appearance of studies which evaluate the results of surgical treatment in refractory forms. One should also mention the evaluation of the role of different components of the innate immune system in the physiopathology and therapeutic potential of IBD. The usefulness of enterography by magnetic resonance has been appraised in different studies, the utility of calprotectin in IBD stools has been re-evaluated by means of a national consensus and different consensuses have been reached in the evaluation of different optimum endpoints for clinical trials on these patients. This line also includes research projects connected with celiac disease and other high-prevalence diarrheic syndromes about which little is known such as the ones arising post-cholecystectomy.
63
CIBEREHD | ANNUAL REPORT 2018